Digital PCR vs qPCR: When Sensitivity and Precision Justify the Cost

Your qPCR puts a rare allele at Cq 36 in three of eight replicates and the standard curve says you are at the assay's detection floor. The question is not whether the signal is real — it is whether qPCR can quantify it well enough to make a decision, or whether the experiment needs digital PCR instead. The trade is sensitivity and precision against throughput, dynamic range, and instrument cost. This comparison walks the criteria that actually decide the platform choice for an existing qPCR lab.

The criteria that decide the platform

Most published comparisons frame this as "absolute quantification (dPCR) vs. relative quantification (qPCR)." That framing is true but unhelpful in practice — a lab running RT-qPCR for gene-expression studies does not switch platforms because of the absolute-vs-relative axis. The decision turns on five criteria:

• Target abundance. How low is the copy number you need to quantify reproducibly? Below ~100 copies per reaction, qPCR's Cq becomes noisy from Poisson sampling alone.
• Required precision on small fold changes. Can the biological question be answered at 2-fold resolution (qPCR's comfort zone), or does it need to discriminate 1.2-fold differences (dPCR territory)?
• Mutant-allele or rare-variant fraction. Detecting a 1-in-10,000 mutant background is qPCR-impossible without massive amplification artifacts.
• Throughput per week. A 96-well qPCR plate runs in ~90 minutes; a 96-sample droplet workflow takes 3–5 hours of hands-on plus instrument time.
• Capital and per-sample budget. qPCR instruments run roughly $5,000–$30,000; droplet and chip-based dPCR systems list at $35,000–$200,000+ before consumables.

Each subsection below names where one platform clearly wins and where the call is closer than vendor marketing implies.

qPCR sensitivity — what the platform delivers and where the floor is

Quantitative PCR measures fluorescence in real time across 35–45 amplification cycles. The cycle at which fluorescence crosses a threshold (Cq) is converted to relative quantity using the ΔΔCt method or to absolute quantity using a standard curve. A modern qPCR assay with primer efficiency between 90% and 110% reliably spans 5–6 orders of magnitude in starting template (roughly Cq 15 to Cq 35).

qPCR's strengths:

• Dynamic range. A well-validated assay quantifies from ~10 to ~10⁷ copies per reaction in one run, no dilution series required.
• Throughput. 96- and 384-well formats with automation move thousands of reactions per day. ~90-minute thermal cycle times mean you can iterate in an afternoon.
• Multiplexing maturity. Hydrolysis-probe duplex and triplex assays are routine; instrument optics commonly resolve 4–6 fluorescent channels. Multiplex compresses experimental cost more than dPCR's per-well multiplexing currently does at most price points.
• Established analysis software. Instrument vendors (Bio-Rad CFX, ABI QuantStudio, Roche LightCycler) ship analysis software; the ΔΔCt workflow is standardized.

qPCR's floor — the places it does not deliver:

• High-Cq quantification is unreliable. Above Cq 35, replicate variance grows quickly and Poisson sampling dominates. A target at <10 copies per reaction will give Cq spreads of >2 cycles between technical replicates — that is 4-fold uncertainty on a measurement that wants to resolve 1.5-fold.
• Small fold changes need huge replication. Resolving a 1.3-fold difference at p < 0.05 typically requires n > 8 biological replicates; the math is in primer efficiency from a standard curve and the related noise calculations.
• Rare-allele detection breaks down. qPCR cannot reliably distinguish a 0.1% mutant population from wild-type background — the wild-type signal overwhelms the mutant Cq window.
• Inhibition is silent until it isn't. Sample inhibitors shift Cq without an obvious warning. A spiked exogenous control catches this, but adding one to every reaction adds cost.

Digital PCR sensitivity — how partitioning changes the math

Digital PCR partitions a sample into thousands to millions of independent micro-reactions (droplets, chip wells, or array partitions). After end-point amplification, each partition is scored as positive (target present) or negative (target absent). Poisson statistics convert the positive fraction to an absolute concentration in copies per microliter — no standard curve required.

The key mechanical fact: a droplet platform such as Bio-Rad's QX200 generates ~20,000 partitions per sample. A chip-based system such as Thermo Fisher's QuantStudio Absolute Q runs ~20,000 microchamber partitions; QIAGEN's QIAcuity platforms run from ~8,500 to ~26,000 depending on plate format. More partitions extend the dynamic range and improve precision at low concentrations, but the per-platform partition count is the upper bound on the concentration range a single dilution can quantify.

What that buys you:

• Precision at low copy numbers. Where qPCR's Cq variance balloons below 100 copies per reaction, dPCR's coefficient of variation is dominated by the partition count, not the input. Practical precision around 10% CV on samples that qPCR would call "near the floor."
• Absolute quantification without a standard curve. No reference material, no curve-fit error, no inter-run calibration drift.
• Rare-allele detection. Mutant-allele fractions as low as 0.001% are detectable with sufficient partition counts — the limit is set by partition number and background false-positive rate, not by exponential amplification dynamics.
• Inhibitor tolerance. Because the readout is end-point positive/negative per partition, mild inhibition that delays amplification still produces the correct positive count.

What dPCR does not buy you:

• Dynamic range in a single run. A 20,000-partition platform saturates above ~100,000 copies per reaction; samples above that need dilution series. qPCR handles this natively.
• Throughput. Droplet workflows add a generation step (droplet maker) and a readout step (droplet reader). 96 samples is a half-day workflow, not the 90-minute qPCR cycle.
• Cost per sample. Reagent cost per dPCR reaction typically runs 3–10x qPCR, even before instrument depreciation. Bio-Rad's public budgeting guidance lists the QX200 platform at ~$38,000 starting capital; chip-based and high-throughput platforms list materially higher.
• Software maturity for relative-expression workflows. Vendor analysis software focuses on absolute counts; doing ΔΔCt-style relative quantification with dPCR data is doable but less standardized.

Side-by-side criteria table

Criterion	qPCR	Digital PCR
Dynamic range, single run	5–6 orders of magnitude	~4 orders (limited by partition count)
Precision at <100 copies/reaction	Poor (Cq variance > 1 cycle)	~10% CV with 20k partitions
Smallest reliable fold change	~2-fold without heavy replication	~1.2-fold
Rare-allele detection floor	~1% mutant-allele fraction	~0.01–0.001% mutant-allele fraction
Absolute quantification	Requires standard curve	Direct from Poisson math
Throughput, 96 samples	~90 minutes total	~3–5 hours total (gen + read)
Inhibitor tolerance	Moderate — shifts Cq silently	High — end-point readout
Instrument capital	$5,000–$30,000	$35,000–$200,000+
Multiplex maturity	4–6 channels, routine	2–5 channels, less standardized at low cost

Verdict by reader-type

If you run gene-expression screens with biological replication and Cq values typically between 18 and 32, pick qPCR. The throughput, dynamic range, and per-sample cost are decisive for screening workloads. Your normalization workflow — validated reference genes, ΔΔCt or Pfaffl analysis, MIQE-compliant reporting — is mature and well-supported.

If you quantify low-abundance targets (rare transcripts, ctDNA, viral load near detection limit, copy-number changes <2-fold), pick digital PCR. The precision improvement at low copy numbers is the dominant signal. Practically: if your qPCR is consistently giving you Cq > 33 with replicate Cq spreads > 1 cycle, you are paying for an answer that dPCR would give cleanly.

If you need both — routine expression screening AND a few low-abundance assays per quarter — the realistic move is to keep qPCR as the workhorse and route specific samples to a core facility's dPCR service. The capital cost of dPCR rarely justifies in-house ownership unless >30% of the lab's reactions are precision-limited.

What this does not change about your qPCR workflow

Switching some assays to dPCR does not change the analytical discipline qPCR demands. Primer efficiency still has to be characterized (efficiency mismatch between samples invalidates ΔΔCt — we cover this in primer efficiency variation across samples). Reference-gene stability still has to be validated for relative quantification. Controls (NTC, NRT, IPC) still belong on every plate. dPCR removes the standard curve and the threshold/baseline questions; it does not remove the biology questions about which gene to normalize against or whether your assay design is specific.

If you are evaluating the switch, the cheapest first step is to run a 12-sample pilot on the same RNA prep using both platforms — ask your vendor reps about loaner runs or pay for a core-facility dPCR run on samples you already have qPCR data for. The agreement plot at low-vs-high Cq tells you exactly where your specific assay falls on the criteria above. AnnealIQ handles the qPCR-side analysis — efficiency-corrected Pfaffl, GeNorm/NormFinder reference-gene validation, MIQE-aligned methods text — for the parts of the workflow you keep on qPCR after the decision.